Island Pharmaceuticals advances in dengue treatment: Completes second phase of ISLA-101 study

Australia-based Island Pharmaceuticals Ltd (ASX: ILA) has achieved a significant milestone in its quest to combat mosquito-borne diseases, particularly dengue. The company announced the successful dosing of all eight subjects in the second cohort of its ISLA-101 Single Ascending Dose (SAD) study. This development marks a crucial step in repurposing ISLA-101 for the prevention and treatment of dengue and similar diseases.

Successful Progress in ISLA-101 SAD Study

The SAD study’s progress comes on the heels of positive feedback from the Safety Review Committee. The committee confirmed that the first cohort of healthy subjects demonstrated good tolerability to ISLA-101, paving the way for the second cohort’s dosing. This study is being conducted at Scientia Clinical Research’s facilities in Sydney, Australia, under the guidance of Contract Research Organisation, Beyond Drug Development.

ISLA-101: A Hope for Dengue Prevention

ISLA-101, known for its potential in antiviral therapy, is undergoing trials to ascertain its efficacy in combating dengue. The current phase involves three cohorts of healthy subjects receiving escalating doses of the drug. The primary aim is to ensure that administered doses can safely achieve blood concentrations effective against the dengue virus.

Looking Ahead: Phase 2a PEACH Clinical Trial

Dr. David Foster, CEO of Island Pharmaceuticals, expressed satisfaction with the study’s progression. “We are pleased that ISLA-101 demonstrated good tolerability in the first dose escalation phase and are now excited to have progressed the dosing of the whole second cohort of subjects,” he stated. The company is on track to complete the third and final cohort, with data read-outs expected in early 2024. These results will inform the planned Phase 2a PEACH clinical trial, a crucial step in the drug’s development journey.

In conclusion, Island Pharmaceuticals’ advancement in the ISLA-101 study represents a beacon of hope in the fight against dengue and other mosquito-borne diseases. With the successful dosing of the second cohort and promising prospects for the upcoming Phase 2a trial, the company is at the forefront of innovative solutions in the realm of antiviral drug development.